{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:05:40Z","timestamp":1791335140918,"version":"4.3.1"},"reference-count":167,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s10787-025-02073-6","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T07:02:30Z","timestamp":1765177350000},"page":"125-144","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Molecular mechanisms and risk factors in rheumatoid arthritis: a comprehensive review"],"prefix":"10.1007","volume":"34","author":[{"given":"Avnesh","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikha","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falguni","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupesh Kumar","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubhan","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaishali","family":"Dobhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"2073_CR1","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1201\/9781003348672-13","volume-title":"Nanotherapeutics for inflammatory arthritis","author":"N Rajdan","year":"2024","unstructured":"Rajdan N, Srivastava B, Sharma K (2024) Rheumatoid arthritis: treatments available at present. In: Mishra V, Pandey RP, Priyadarshini A, Chang CM, Leal E (eds) Nanotherapeutics for inflammatory arthritis, 1st edn. CRC, Boca Raton, pp 243\u2013295","edition":"1"},{"key":"2073_CR2","first-page":"271","volume-title":"Internal medicine for dental treatments: patients with medical diseases","author":"Y Matsukawa","year":"2024","unstructured":"Matsukawa Y et al (2024) Immune system diseases. In: Chiba T, Yamada H (eds) Internal medicine for dental treatments: patients with medical diseases. Springer, Singapore, pp 271\u2013294"},{"issue":"1","key":"2073_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.4236\/ojra.2023.131003","volume":"13","author":"M Kolou","year":"2023","unstructured":"Kolou M (2023) Challenges of rheumatoid arthritis management in sub-saharan Africa in the 21st century. OJRA 13(1):17\u201340","journal-title":"OJRA"},{"key":"2073_CR4","doi-asserted-by":"publisher","first-page":"689698","DOI":"10.3389\/fmed.2021.689698","volume":"8","author":"VC Rom\u00e3o","year":"2021","unstructured":"Rom\u00e3o VC, Fonseca JE (2021) Etiology and risk factors for rheumatoid arthritis: a state-of-the-art review. Front Med 8:689698","journal-title":"Front Med"},{"key":"2073_CR5","unstructured":"Jiang X (2015) Gene-environment interactions in rheumatoid arthritis: quantification and characterization of contributing factors. Sweden: Karolinska Institutet. Thesis. https:\/\/hdl.handle.net\/10616\/44690"},{"issue":"1","key":"2073_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41577-022-00727-y","volume":"23","author":"E Miyauchi","year":"2023","unstructured":"Miyauchi E et al (2023) The impact of the gut microbiome on extra-intestinal autoimmune diseases. Nat Rev Immunol 23(1):9\u201323","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"2073_CR7","first-page":"591","volume":"18","author":"A Finckh","year":"2022","unstructured":"Finckh A et al (2022) Global epidemiology of rheumatoid arthritis. Nat Rev Rheumatol 18(10):591\u2013602","journal-title":"Nat Rev Rheumatol"},{"key":"2073_CR8","doi-asserted-by":"crossref","unstructured":"Brown P, Pratt AG, Hyrich KL (2024) Therapeutic advances in rheumatoid arthritis. BMJ 384","DOI":"10.1136\/bmj-2022-070856"},{"issue":"SI3","key":"2073_CR9","doi-asserted-by":"publisher","first-page":"SI260","DOI":"10.1093\/rheumatology\/kead489","volume":"62","author":"S Surandran","year":"2023","unstructured":"Surandran S et al (2023) Multimorbidity in rheumatoid arthritis: common mechanistic links and impact and challenges in routine clinical practice. Rheumatology 62(SI3):SI260\u2013SI270","journal-title":"Rheumatology"},{"issue":"12","key":"2073_CR10","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/s41584-024-01169-7","volume":"20","author":"V Konzett","year":"2024","unstructured":"Konzett V, Aletaha D (2024) Management strategies in rheumatoid arthritis. Nat Rev Rheumatol 20(12):760\u2013769","journal-title":"Nat Rev Rheumatol"},{"key":"2073_CR11","doi-asserted-by":"publisher","first-page":"119034","DOI":"10.1016\/j.lfs.2021.119034","volume":"269","author":"F Moadab","year":"2021","unstructured":"Moadab F, Khorramdelazad H, Abbasifard M (2021) Role of CCL2\/CCR2 axis in the Immunopathogenesis of rheumatoid arthritis: latest evidence and therapeutic approaches. Life Sci 269:119034","journal-title":"Life Sci"},{"key":"2073_CR12","doi-asserted-by":"publisher","unstructured":"Lopez OI, Malcolm J, Culshaw S (2024) Periodontitis and rheumatoid arthritis\u2014global efforts to untangle two complex diseases. Periodontology 2000. https:\/\/doi.org\/10.1111\/prd.12530","DOI":"10.1111\/prd.12530"},{"issue":"11","key":"2073_CR13","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.3390\/cells10112857","volume":"10","author":"AF Radu","year":"2021","unstructured":"Radu AF, Bungau SG (2021) Management of rheumatoid arthritis: an overview. Cells 10(11):2857","journal-title":"Cells"},{"issue":"2","key":"2073_CR14","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.bj.2020.06.010","volume":"44","author":"MI Edilova","year":"2021","unstructured":"Edilova MI, Akram A, Abdul-Sater AA (2021) Innate immunity drives pathogenesis of rheumatoid arthritis. Biomed J 44(2):172\u2013182","journal-title":"Biomedical J"},{"key":"2073_CR15","doi-asserted-by":"publisher","first-page":"867260","DOI":"10.3389\/fimmu.2022.867260","volume":"13","author":"M Cutolo","year":"2022","unstructured":"Cutolo M et al (2022) The role of M1\/M2 macrophage polarization in rheumatoid arthritis synovitis. Front Immunol 13:867260","journal-title":"Front Immunol"},{"issue":"6","key":"2073_CR16","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.3390\/antiox11061153","volume":"11","author":"X Wang","year":"2022","unstructured":"Wang X et al (2022) The role of reactive oxygen species in the rheumatoid arthritis-associated synovial microenvironment. Antioxidants 11(6):1153","journal-title":"Antioxidants"},{"issue":"8","key":"2073_CR17","doi-asserted-by":"publisher","first-page":"941","DOI":"10.3390\/ph15080941","volume":"15","author":"D Ba\u010denkov\u00e1","year":"2022","unstructured":"Ba\u010denkov\u00e1 D et al (2022) Interaction between mesenchymal stem cells and the immune system in rheumatoid arthritis. Pharmaceuticals 15(8):941","journal-title":"Pharmaceuticals"},{"issue":"1","key":"2073_CR18","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s10753-022-01751-9","volume":"46","author":"M Masoumi","year":"2023","unstructured":"Masoumi M et al (2023) Role of T cells in the pathogenesis of rheumatoid arthritis: focus on immunometabolism dysfunctions. Inflammation 46(1):88\u2013102","journal-title":"Inflammation"},{"issue":"20","key":"2073_CR19","doi-asserted-by":"publisher","first-page":"10922","DOI":"10.3390\/ijms222010922","volume":"22","author":"N Kondo","year":"2021","unstructured":"Kondo N, Kuroda T, Kobayashi D (2021) Cytokine networks in the pathogenesis of rheumatoid arthritis. Int J Mol Sci 22(20):10922","journal-title":"Int J Mol Sci"},{"issue":"22","key":"2073_CR20","doi-asserted-by":"publisher","first-page":"12082","DOI":"10.3390\/ijms252212082","volume":"25","author":"V Panichi","year":"2024","unstructured":"Panichi V et al (2024) Innate immunity and synovitis: key players in osteoarthritis progression. Int J Mol Sci 25(22):12082","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2073_CR21","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1007\/s10753-020-01371-1","volume":"44","author":"M Masoumi","year":"2021","unstructured":"Masoumi M et al (2021) Destructive roles of fibroblast-like synoviocytes in chronic inflammation and joint damage in rheumatoid arthritis. Inflammation 44(2):466\u2013479","journal-title":"Inflammation"},{"issue":"9","key":"2073_CR22","doi-asserted-by":"publisher","first-page":"6619","DOI":"10.1007\/s11033-021-06672-8","volume":"48","author":"FRC Moreira","year":"2021","unstructured":"Moreira FRC et al (2021) The role of Renin angiotensin system in the pathophysiology of rheumatoid arthritis. Mol Biol Rep 48(9):6619\u20136629","journal-title":"Mol Biol Rep"},{"issue":"5","key":"2073_CR23","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.3390\/ijms23052871","volume":"23","author":"K Maeda","year":"2022","unstructured":"Maeda K et al (2022) Inflammation and bone metabolism in rheumatoid arthritis: molecular mechanisms of joint destruction and pharmacological treatments. Int J Mol Sci 23(5):2871","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2073_CR24","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41392-023-01331-9","volume":"8","author":"Q Ding","year":"2023","unstructured":"Ding Q et al (2023) Signaling pathways in rheumatoid arthritis: implications for targeted therapy. Signal Transduct Target Therapy 8(1):68","journal-title":"Signal Transduct Target Therapy"},{"issue":"3","key":"2073_CR25","first-page":"e162","volume":"3","author":"J Huang","year":"2022","unstructured":"Huang J et al (2022) Molecular mechanisms and therapeutic target of NETosis in diseases. Med Comm 3(3):e162","journal-title":"Med Comm"},{"issue":"11","key":"2073_CR26","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.3390\/cells10113017","volume":"10","author":"AL Mueller","year":"2021","unstructured":"Mueller AL et al (2021) Recent advances in Understanding the pathogenesis of rheumatoid arthritis: new treatment strategies. Cells 10(11):3017","journal-title":"Cells"},{"key":"2073_CR27","doi-asserted-by":"crossref","unstructured":"Unterberger S et al (2021) Contribution of toll-like receptors and the NLRP3 inflammasome in rheumatoid arthritis pathophysiology. ImmunoTargets Therapy 285\u2013298","DOI":"10.2147\/ITT.S288547"},{"issue":"1","key":"2073_CR28","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s11914-024-00900-3","volume":"23","author":"K Carroll","year":"2025","unstructured":"Carroll K, Sawden M, DAMPs SS (2025) PAMPs, NLRs, RIGs, CLRs and TLRs\u2013understanding the alphabet soup in the context of bone biology. Curr Osteoporos Rep 23(1):6","journal-title":"Curr Osteoporos Rep"},{"issue":"6","key":"2073_CR29","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.3390\/antiox11061151","volume":"11","author":"MJ L\u00f3pez-Armada","year":"2022","unstructured":"L\u00f3pez-Armada MJ, Fern\u00e1ndez-Rodr\u00edguez JA, Blanco FJ (2022) Mitochondrial dysfunction and oxidative stress in rheumatoid arthritis. Antioxidants 11(6):1151","journal-title":"Antioxidants"},{"issue":"7","key":"2073_CR30","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1080\/08916934.2021.1963959","volume":"54","author":"G Kaur","year":"2021","unstructured":"Kaur G, Sharma A, Bhatnagar A (2021) Role of oxidative stress in pathophysiology of rheumatoid arthritis: insights into NRF2-KEAP1 signalling. Autoimmunity 54(7):385\u2013397","journal-title":"Autoimmunity"},{"key":"2073_CR31","doi-asserted-by":"crossref","unstructured":"Peng R et al (2025) The basic and research progress of joint barrier dysfunction in joint diseases. Guidelines and Standards in Chinese Medicine, pp 10.1097","DOI":"10.1097\/gscm.2500000000000067"},{"issue":"10","key":"2073_CR32","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/s41584-021-00682-3","volume":"17","author":"J Tuckermann","year":"2021","unstructured":"Tuckermann J, Adams RH (2021) The endothelium\u2013bone axis in development, homeostasis and bone and joint disease. Nat Rev Rheumatol 17(10):608\u2013620","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"2073_CR33","first-page":"169","volume":"36","author":"SB Kresno","year":"2004","unstructured":"Kresno SB, Gondhowiardjo S (2004) Disregulation process of cancer cell proliferation. Acta Med Indones 36(3):169\u2013176","journal-title":"Acta Med Indones"},{"issue":"10","key":"2073_CR34","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.3390\/biomedicines12102292","volume":"12","author":"G Di Cicco","year":"2024","unstructured":"Di Cicco G et al (2024) The pathogenetic role of RANK\/RANKL\/OPG signaling in osteoarthritis and related targeted therapies. Biomedicines 12(10):2292","journal-title":"Biomedicines"},{"issue":"3","key":"2073_CR35","first-page":"283","volume":"2","author":"D K\u0131l\u0131\u00e7","year":"2021","unstructured":"K\u0131l\u0131\u00e7 D, Erba\u015f O (2021) Osteoprotegerin and RANKL levels of gingival crevicular fluid in periodontal disease. J Exp Basic Med Sci 2(3):283\u2013288","journal-title":"J Experimental Basic Med Sci"},{"key":"2073_CR36","doi-asserted-by":"publisher","first-page":"790122","DOI":"10.3389\/fimmu.2021.790122","volume":"12","author":"J Zhao","year":"2021","unstructured":"Zhao J et al (2021) Molecular and cellular heterogeneity in rheumatoid arthritis: mechanisms and clinical implications. Front Immunol 12:790122","journal-title":"Front Immunol"},{"issue":"12","key":"2073_CR37","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.3390\/genes13122388","volume":"13","author":"S Jarmakiewicz-Czaja","year":"2022","unstructured":"Jarmakiewicz-Czaja S et al (2022) Genetic and epigenetic etiology of inflammatory bowel disease: an update. Genes 13(12):2388","journal-title":"Genes"},{"issue":"8","key":"2073_CR38","doi-asserted-by":"publisher","first-page":"103311","DOI":"10.1016\/j.sjbs.2022.103311","volume":"29","author":"DS Alshaya","year":"2022","unstructured":"Alshaya DS (2022) Genetic and epigenetic factors associated with depression: an updated overview. Saudi J Biol Sci 29(8):103311","journal-title":"Saudi J Biol Sci"},{"key":"2073_CR39","doi-asserted-by":"publisher","first-page":"goac035","DOI":"10.1093\/gastro\/goac035","volume":"10","author":"S Parmar","year":"2022","unstructured":"Parmar S, Easwaran H (2022) Genetic and epigenetic dependencies in colorectal cancer development. Gastroenterol Rep 10:goac035","journal-title":"Gastroenterol Rep"},{"issue":"5","key":"2073_CR40","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.3390\/ijms22052412","volume":"22","author":"P Ntontsi","year":"2021","unstructured":"Ntontsi P et al (2021) Genetics and epigenetics in asthma. Int J Mol Sci 22(5):2412","journal-title":"Int J Mol Sci"},{"key":"2073_CR41","doi-asserted-by":"publisher","first-page":"11","DOI":"10.21037\/tgh-23-31","volume":"9","author":"B Njei","year":"2023","unstructured":"Njei B et al (2023) Genetic and epigenetic determinants of non-alcoholic fatty liver disease (NAFLD) in lean individuals: a systematic review. Transl Gastroenterol Hepatol 9:11","journal-title":"Translational Gastroenterol Hepatol"},{"issue":"16","key":"2073_CR42","doi-asserted-by":"publisher","first-page":"8697","DOI":"10.3390\/ijerph18168697","volume":"18","author":"F Giamb\u00f2","year":"2021","unstructured":"Giamb\u00f2 F et al (2021) Genetic and epigenetic alterations induced by pesticide exposure: integrated analysis of gene expression, MicroRNA expression, and DNA methylation datasets. Int J Environ Res Public Health 18(16):8697","journal-title":"Int J Environ Res Public Health"},{"issue":"22","key":"2073_CR43","doi-asserted-by":"publisher","first-page":"12170","DOI":"10.3390\/ijms222212170","volume":"22","author":"M Payet","year":"2021","unstructured":"Payet M et al (2021) Epigenetic regulation (including micro-RNAs, DNA methylation and histone modifications) of rheumatoid arthritis: a systematic review. Int J Mol Sci 22(22):12170","journal-title":"Int J Mol Sci"},{"key":"2073_CR44","doi-asserted-by":"publisher","first-page":"859400","DOI":"10.3389\/fimmu.2022.859400","volume":"13","author":"C Yang","year":"2022","unstructured":"Yang C et al (2022) Epigenetic regulation in the pathogenesis of rheumatoid arthritis. Front Immunol 13:859400","journal-title":"Front Immunol"},{"key":"2073_CR45","doi-asserted-by":"crossref","unstructured":"Ergin K, \u00c7etinkaya R (2021) Regulation of microRNAs, in mirnomics: MicroRNA biology and computational analysis. Springer, pp 1\u201332","DOI":"10.1007\/978-1-0716-1170-8_1"},{"key":"2073_CR46","doi-asserted-by":"crossref","unstructured":"Liao H et al (2024) NF-\u03baB signaling pathway in rheumatoid arthritis: mechanisms and therapeutic potential. Mol Neurobiol. pp 1\u201324","DOI":"10.1007\/s12035-024-04634-2"},{"key":"2073_CR47","doi-asserted-by":"publisher","first-page":"662047","DOI":"10.3389\/fmolb.2021.662047","volume":"8","author":"AL Carvalho","year":"2021","unstructured":"Carvalho AL, Hedrich CM (2021) The molecular pathophysiology of psoriatic arthritis\u2014the complex interplay between genetic predisposition, epigenetics factors, and the Microbiome. Front Mol Biosci 8:662047","journal-title":"Front Mol Biosci"},{"issue":"3","key":"2073_CR48","doi-asserted-by":"publisher","first-page":"R118","DOI":"10.1186\/ar3848","volume":"14","author":"SC Law","year":"2012","unstructured":"Law SC et al (2012) T-cell autoreactivity to citrullinated autoantigenic peptides in rheumatoid arthritis patients carrying HLA-DRB1 shared epitope alleles. Arthritis Res Therapy 14(3):R118","journal-title":"Arthritis Res Therapy"},{"issue":"10","key":"2073_CR49","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1080\/10985549.2024.2378810","volume":"44","author":"RJ Brownlie","year":"2024","unstructured":"Brownlie RJ, Salmond RJ (2024) Regulation of T cell signaling and immune responses by PTPN22. Mol Cell Biol 44(10):443\u2013452","journal-title":"Mol Cell Biol"},{"key":"2073_CR50","doi-asserted-by":"publisher","first-page":"155835","DOI":"10.1016\/j.cyto.2022.155835","volume":"152","author":"Y-m Zhong","year":"2022","unstructured":"Zhong Y-m et al (2022) Moxibustion regulates the polarization of macrophages through the IL-4\/STAT6 pathway in rheumatoid arthritis. Cytokine 152:155835","journal-title":"Cytokine"},{"issue":"7","key":"2073_CR51","doi-asserted-by":"publisher","first-page":"864","DOI":"10.3390\/biom14070864","volume":"14","author":"A Mirzaesmaeili","year":"2024","unstructured":"Mirzaesmaeili A, Abdul-Sater AA (2024) TRAF1 deficiency in macrophages drives exacerbated joint inflammation in rheumatoid arthritis. Biomolecules 14(7):864","journal-title":"Biomolecules"},{"key":"2073_CR52","doi-asserted-by":"publisher","first-page":"615941","DOI":"10.3389\/fimmu.2020.615941","volume":"11","author":"S Wang","year":"2021","unstructured":"Wang S et al (2021) Immune checkpoint-related gene polymorphisms are associated with primary immune thrombocytopenia. Front Immunol 11:615941","journal-title":"Front Immunol"},{"issue":"15","key":"2073_CR53","doi-asserted-by":"publisher","first-page":"8275","DOI":"10.3390\/ijms25158275","volume":"25","author":"E Bagyinszky","year":"2024","unstructured":"Bagyinszky E, An SSA (2024) Genetic mutations associated with TNFAIP3 (A20) haploinsufficiency and their impact on inflammatory diseases. Int J Mol Sci 25(15):8275","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2073_CR54","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.3390\/ijms23042106","volume":"23","author":"OM Koper-Lenkiewicz","year":"2022","unstructured":"Koper-Lenkiewicz OM et al (2022) Proinflammatory cytokines (IL-1,-6,-8,-15,-17,-18,-23, TNF-\u03b1) single nucleotide polymorphisms in rheumatoid arthritis\u2014a literature review. Int J Mol Sci 23(4):2106","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2073_CR55","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s10067-020-05255-5","volume":"40","author":"M Vecellio","year":"2021","unstructured":"Vecellio M et al (2021) The multifaceted functional role of DNA methylation in immune-mediated rheumatic diseases. Clin Rheumatol 40(2):459\u2013476","journal-title":"Clin Rheumatol"},{"issue":"13","key":"2073_CR56","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.3390\/cells12131749","volume":"12","author":"Y Zhang","year":"2023","unstructured":"Zhang Y et al (2023) Role of MiRNAs in rheumatoid arthritis therapy. Cells 12(13):1749","journal-title":"Cells"},{"key":"2073_CR57","doi-asserted-by":"publisher","first-page":"652751","DOI":"10.3389\/fphar.2021.652751","volume":"12","author":"C Miao","year":"2021","unstructured":"Miao C et al (2021) Dysregulation of LncRNAs in rheumatoid arthritis: biomarkers, pathogenesis and potential therapeutic targets. Front Pharmacol 12:652751","journal-title":"Front Pharmacol"},{"issue":"1","key":"2073_CR58","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12915-021-01011-6","volume":"19","author":"D Zong","year":"2021","unstructured":"Zong D et al (2021) Chromatin accessibility landscapes of immune cells in rheumatoid arthritis nominate monocytes in disease pathogenesis. BMC Biol 19(1):79","journal-title":"BMC Biol"},{"issue":"6","key":"2073_CR59","doi-asserted-by":"publisher","first-page":"e20211487","DOI":"10.1084\/jem.20211487","volume":"219","author":"N Jiwrajka","year":"2022","unstructured":"Jiwrajka N, Anguera MC (2022) The X in seX-biased immunity and autoimmune rheumatic disease. J Exp Med 219(6):e20211487","journal-title":"J Exp Med"},{"issue":"23","key":"2073_CR60","doi-asserted-by":"publisher","first-page":"7179","DOI":"10.3390\/jcm11237179","volume":"11","author":"C Sch\u00e4fer","year":"2022","unstructured":"Sch\u00e4fer C, Key\u00dfer G (2022) Lifestyle factors and their influence on rheumatoid arthritis: a narrative review. J Clin Med 11(23):7179","journal-title":"J Clin Med"},{"issue":"4","key":"2073_CR61","doi-asserted-by":"publisher","first-page":"404","DOI":"10.31138\/mjr.301223.eaf","volume":"34","author":"AI Venetsanopoulou","year":"2023","unstructured":"Venetsanopoulou AI et al (2023) Epidemiology and risk factors for rheumatoid arthritis development. Mediterranean J Rheumatol 34(4):404","journal-title":"Mediterranean J Rheumatol"},{"issue":"4","key":"2073_CR62","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.rdc.2022.06.003","volume":"48","author":"N Desai","year":"2022","unstructured":"Desai N, Federico L, Baker JF (2022) Lifestyle, hormonal, and metabolic environmental risks for rheumatoid arthritis. Rheumatic Disease Clin 48(4):799\u2013811","journal-title":"Rheumatic Disease Clin"},{"issue":"9","key":"2073_CR63","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1080\/1744666X.2022.2106970","volume":"18","author":"AI Venetsanopoulou","year":"2022","unstructured":"Venetsanopoulou AI et al (2022) Epidemiology of rheumatoid arthritis: genetic and environmental influences. Expert Rev Clin Immunol 18(9):923\u2013931","journal-title":"Expert Rev Clin Immunol"},{"issue":"7","key":"2073_CR64","doi-asserted-by":"publisher","first-page":"103333","DOI":"10.1016\/j.autrev.2023.103333","volume":"22","author":"E Nikiphorou","year":"2023","unstructured":"Nikiphorou E, Philippou E (2023) Nutrition and its role in prevention and management of rheumatoid arthritis. Autoimmun Rev 22(7):103333","journal-title":"Autoimmun Rev"},{"issue":"1","key":"2073_CR65","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s10067-017-3821-4","volume":"37","author":"D Zhong","year":"2018","unstructured":"Zhong D et al (2018) The role of gut microbiota in the pathogenesis of rheumatic diseases. Clin Rheumatol 37(1):25\u201334","journal-title":"Clin Rheumatol"},{"key":"2073_CR66","doi-asserted-by":"publisher","first-page":"668898","DOI":"10.3389\/fmed.2021.668898","volume":"8","author":"M Novella-Navarro","year":"2021","unstructured":"Novella-Navarro M et al (2021) Risk factors for developing rheumatoid arthritis in patients with undifferentiated arthritis and inflammatory arthralgia. Front Med 8:668898","journal-title":"Front Med"},{"key":"2073_CR67","doi-asserted-by":"publisher","first-page":"1456145","DOI":"10.3389\/fimmu.2024.1456145","volume":"15","author":"MY Choi","year":"2024","unstructured":"Choi MY, Costenbader KH, Fritzler MJ (2024) Environment and systemic autoimmune rheumatic diseases: an overview and future directions. Front Immunol 15:1456145","journal-title":"Front Immunol"},{"issue":"5","key":"2073_CR68","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/imj.15537","volume":"52","author":"L Koller-Smith","year":"2022","unstructured":"Koller-Smith L et al (2022) Rheumatoid arthritis is a preventable disease: 11 ways to reduce your patients\u2019 risk. Intern Med J 52(5):711\u2013716","journal-title":"Intern Med J"},{"issue":"1","key":"2073_CR69","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1017\/S0007114524002721","volume":"133","author":"Y Wang","year":"2025","unstructured":"Wang Y et al (2025) Dietary factors and rheumatoid arthritis: new perspectives from a Mendelian randomisation analysis. Br J Nutr 133(1):107\u2013117. https:\/\/doi.org\/10.1017\/S0007114524002721","journal-title":"Br J Nutr"},{"issue":"9","key":"2073_CR70","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1038\/s41430-025-01628-8","volume":"79","author":"P Hu","year":"2025","unstructured":"Hu P et al (2025) Mediterranean diet and rheumatoid arthritis: a nine-year cohort study and systematic review with meta-analysis. Eur J Clin Nutr 79(9):888\u2013896. https:\/\/doi.org\/10.1038\/s41430-025-01628-8","journal-title":"Eur J Clin Nutr"},{"issue":"11","key":"2073_CR71","doi-asserted-by":"publisher","first-page":"e48625","DOI":"10.7759\/cureus.48625","volume":"15","author":"KV Shekhar","year":"2023","unstructured":"Shekhar KV, Pathak MM, Pisulkar G (2023) Diet and lifestyle impact on rheumatoid arthritis: a comprehensive review. Cureus 15(11):e48625. https:\/\/doi.org\/10.7759\/cureus.48625","journal-title":"Cureus"},{"issue":"7","key":"2073_CR72","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1002\/art.42463","volume":"75","author":"E L\u00f6nnblom","year":"2023","unstructured":"L\u00f6nnblom E et al (2023) Autoantibodies to disease-related proteins in joints as novel biomarkers for the diagnosis of rheumatoid arthritis. Arthritis Rheumatol 75(7):1110\u20131119","journal-title":"Arthritis Rheumatol"},{"key":"2073_CR73","doi-asserted-by":"publisher","first-page":"685312","DOI":"10.3389\/fimmu.2021.685312","volume":"12","author":"J R\u00f6nnelid","year":"2021","unstructured":"R\u00f6nnelid J, Turesson C, Kastbom A (2021) Autoantibodies in rheumatoid arthritis\u2013laboratory and clinical perspectives. Front Immunol 12:685312","journal-title":"Front Immunol"},{"issue":"10","key":"2073_CR74","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1080\/14737159.2023.2247986","volume":"23","author":"NH Trier","year":"2023","unstructured":"Trier NH, Houen G (2023) Anti-citrullinated protein antibodies as biomarkers in rheumatoid arthritis. Expert Rev Mol Diagn 23(10):895\u2013911","journal-title":"Expert Rev Mol Diagn"},{"issue":"8","key":"2073_CR75","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.25122\/jml-2023-0158","volume":"16","author":"HAA Khudhair","year":"2023","unstructured":"Khudhair HAA (2023) A study of the roles of some immunological biomarkers in the diagnosis of rheumatoid arthritis. J Med Life 16(8):1194","journal-title":"J Med Life"},{"issue":"3","key":"2073_CR76","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1080\/00325481.2022.2052626","volume":"135","author":"D Abdelhafiz","year":"2023","unstructured":"Abdelhafiz D et al (2023) Biomarkers for the diagnosis and treatment of rheumatoid arthritis\u2013a systematic review. Postgrad Med 135(3):214\u2013223","journal-title":"Postgrad Med"},{"issue":"12","key":"2073_CR77","doi-asserted-by":"publisher","first-page":"e743","DOI":"10.1016\/S2665-9913(23)00242-4","volume":"5","author":"S Bugatti","year":"2023","unstructured":"Bugatti S et al (2023) Autoantibody-negative rheumatoid arthritis: still a challenge for the rheumatologist. Lancet Rheumatol 5(12):e743\u2013e755","journal-title":"Lancet Rheumatol"},{"issue":"9","key":"2073_CR78","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.3390\/biomedicines10092150","volume":"10","author":"H Gra\u00dfhoff","year":"2022","unstructured":"Gra\u00dfhoff H et al (2022) Autoantibodies as biomarker and therapeutic target in systemic sclerosis. Biomedicines 10(9):2150","journal-title":"Biomedicines"},{"issue":"1","key":"2073_CR79","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1016\/S2665-9913(21)00254-X","volume":"4","author":"FA Cooles","year":"2022","unstructured":"Cooles FA, Isaacs JD (2022) The interferon gene signature as a clinically relevant biomarker in autoimmune rheumatic disease. Lancet Rheumatol 4(1):e61\u2013e72","journal-title":"Lancet Rheumatol"},{"issue":"2","key":"2073_CR80","doi-asserted-by":"publisher","first-page":"e002512","DOI":"10.1136\/rmdopen-2022-002512","volume":"8","author":"F Ponchel","year":"2022","unstructured":"Ponchel F et al (2022) Added value of multiple autoantibody testing for predicting progression to inflammatory arthritis in at-risk individuals. RMD Open 8(2):e002512","journal-title":"RMD Open"},{"issue":"2","key":"2073_CR81","first-page":"e498","volume":"28","author":"N Ghosh","year":"2022","unstructured":"Ghosh N et al (2022) Autoantibodies in patients with immune-related adverse events from checkpoint inhibitors: a systematic literature review. JCR J Clin Rheumatol 28(2):e498\u2013e505","journal-title":"JCR: J Clin Rheumatol"},{"key":"2073_CR82","doi-asserted-by":"publisher","first-page":"627986","DOI":"10.3389\/fimmu.2021.627986","volume":"12","author":"C Gr\u00f6nwall","year":"2021","unstructured":"Gr\u00f6nwall C et al (2021) A comprehensive evaluation of the relationship between different IgG and IgA anti-modified protein autoantibodies in rheumatoid arthritis. Front Immunol 12:627986","journal-title":"Front Immunol"},{"key":"2073_CR83","doi-asserted-by":"publisher","first-page":"1016263","DOI":"10.3389\/fimmu.2022.1016263","volume":"13","author":"A Nicol\u00f2","year":"2022","unstructured":"Nicol\u00f2 A et al (2022) Rheumatoid factor IgM autoantibodies control IgG homeostasis. Front Immunol 13:1016263","journal-title":"Front Immunol"},{"issue":"1","key":"2073_CR84","doi-asserted-by":"publisher","first-page":"e001228","DOI":"10.1136\/rmdopen-2020-001228","volume":"7","author":"A Catrina","year":"2021","unstructured":"Catrina A, Krishnamurthy A, Rethi B (2021) Current view on the pathogenic role of anti-citrullinated protein antibodies in rheumatoid arthritis. RMD Open 7(1):e001228","journal-title":"RMD Open"},{"issue":"1","key":"2073_CR85","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1134\/S1607672924700960","volume":"517","author":"DA Dibrov","year":"2024","unstructured":"Dibrov DA et al (2024) Anti-Carbamylated protein antibodies in ACPA-negative and ACPA-Positive patients with rheumatoid arthritis. Dokl Biochem Biophys 517(1):235\u2013242 Epub 2024 Jul 13. PMID: 39002007","journal-title":"Dokl Biochem Biophys"},{"issue":"2","key":"2073_CR86","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3233\/HAB-240007","volume":"32","author":"A Hagras","year":"2024","unstructured":"Hagras A et al (2024) Clinical significance of anti-mutated citrullinated vimentin antibodies in rheumatoid arthritis patients. Hum Antib 32(2):75\u201383","journal-title":"Hum Antib"},{"issue":"2","key":"2073_CR87","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s10787-023-01149-5","volume":"31","author":"DS Padhy","year":"2023","unstructured":"Padhy DS et al (2023) Selective Inhibition of peptidyl-arginine deiminase (PAD): can it control multiple inflammatory disorders as a promising therapeutic strategy? Inflammopharmacology 31(2):731\u2013744","journal-title":"Inflammopharmacology"},{"key":"2073_CR88","doi-asserted-by":"crossref","unstructured":"Han Y et al (2025) Anti-SSA\/SSB antibody double-negative Sj\u00f6gren\u2019s disease patients: a comprehensive clinical study and immune profile. Clin Rheumatol. pp 1\u20139","DOI":"10.1007\/s10067-024-07295-7"},{"key":"2073_CR89","doi-asserted-by":"publisher","first-page":"1237729","DOI":"10.3389\/fimmu.2023.1237729","volume":"14","author":"SA Rizo-T\u00e9llez","year":"2023","unstructured":"Rizo-T\u00e9llez SA, Sekheri M, Filep JG (2023) C-reactive protein: a target for therapy to reduce inflammation. Front Immunol 14:1237729","journal-title":"Front Immunol"},{"issue":"1","key":"2073_CR90","doi-asserted-by":"publisher","first-page":"14","DOI":"10.64229\/yh1y6w35","volume":"1","author":"EOO Raluchukwu","year":"2025","unstructured":"Raluchukwu EOO et al (2025) Status of erythrocyte sedimentation Rate, platelet counts and serum phosphate in patients with rheumatoid arthritis in Owerri. Global Health Dynamics 1(1):14\u201319","journal-title":"Global Health Dynamics"},{"key":"2073_CR91","doi-asserted-by":"publisher","first-page":"631299","DOI":"10.3389\/fimmu.2020.631299","volume":"11","author":"HI Sori\u0107","year":"2021","unstructured":"Sori\u0107 HI, Kos I, Lamot L (2021) Serum amyloid A in inflammatory rheumatic diseases: a compendious review of a renowned biomarker. Front Immunol 11:631299","journal-title":"Front Immunol"},{"issue":"4","key":"2073_CR92","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.3390\/jcm12041630","volume":"12","author":"GM Leone","year":"2023","unstructured":"Leone GM et al (2023) Past, present and (foreseeable) future of biological anti-TNF alpha therapy. J Clin Med 12(4):1630","journal-title":"J Clin Med"},{"issue":"11","key":"2073_CR93","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1248\/bpb.30.2001","volume":"30","author":"Y Ohsugi","year":"2007","unstructured":"Ohsugi Y (2007) Recent advances in immunopathophysiology of interleukin-6: an innovative therapeutic drug, Tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases. Biol Pharm Bull 30(11):2001\u20132006","journal-title":"Biol Pharm Bull"},{"issue":"3","key":"2073_CR94","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ejr.2016.01.001","volume":"38","author":"S Fadda","year":"2016","unstructured":"Fadda S et al (2016) Serum matrix metalloproteinase-3 in rheumatoid arthritis patients: correlation with disease activity and joint destruction. Egypt Rheumatologist 38(3):153\u2013159","journal-title":"Egypt Rheumatologist"},{"issue":"3","key":"2073_CR95","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jbspin.2012.09.001","volume":"80","author":"J Strunk","year":"2013","unstructured":"Strunk J et al (2013) Linking systemic angiogenic factors (VEGF, angiogenin, TIMP-2) and doppler ultrasound to anti-inflammatory treatment in rheumatoid arthritis. Joint Bone Spine 80(3):270\u2013273","journal-title":"Joint Bone Spine"},{"issue":"4","key":"2073_CR96","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.berh.2019.01.010","volume":"32","author":"O Shovman","year":"2018","unstructured":"Shovman O et al (2018) The diagnostic value of 14-3-3\u03b7 protein levels in patients with rheumatoid arthritis. Best Pract Res Clin Rheumatol 32(4):610\u2013617","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"8","key":"2073_CR97","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1177\/1535370216681551","volume":"242","author":"F Ometto","year":"2017","unstructured":"Ometto F et al (2017) Calprotectin in rheumatic diseases. Exp Biol Med 242(8):859\u2013873","journal-title":"Experimental Biology Med"},{"issue":"178","key":"2073_CR98","doi-asserted-by":"publisher","first-page":"178ra40","DOI":"10.1126\/scitranslmed.3005580","volume":"5","author":"R Khandpur","year":"2013","unstructured":"Khandpur R et al (2013) NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci Transl Med 5(178):178ra40\u2013178ra40","journal-title":"Sci Transl Med"},{"issue":"1","key":"2073_CR99","doi-asserted-by":"publisher","first-page":"23","DOI":"10.12701\/jyms.2022.00773","volume":"40","author":"JS Kong","year":"2023","unstructured":"Kong JS, Jeong GH, Yoo SA (2023) The use of animal models in rheumatoid arthritis research. J Yeungnam Med Sci 40(1):23\u201329","journal-title":"J Yeungnam Med Sci"},{"issue":"7","key":"2073_CR100","doi-asserted-by":"publisher","first-page":"56","DOI":"10.14715\/cmb\/2025.71.7.8","volume":"71","author":"SSS Blbas","year":"2025","unstructured":"Blbas SSS, Fatah HR, Blbas SSI (2025) Anti-inflammatory effect of thyme on rheumatoid arthritis in animal model. Cell Mol Biol 71(7):56\u201363","journal-title":"Cell Mol Biol"},{"issue":"1","key":"2073_CR101","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3390\/biomedicines10010044","volume":"10","author":"A Markovics","year":"2021","unstructured":"Markovics A et al (2021) Restoring the balance between pro-inflammatory and anti-inflammatory cytokines in the treatment of rheumatoid arthritis: new insights from animal models. Biomedicines 10(1):44","journal-title":"Biomedicines"},{"issue":"6","key":"2073_CR102","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s00726-021-02988-8","volume":"53","author":"MA Malek","year":"2021","unstructured":"Malek MA, Javadivala Z (2021) A systematic review of preclinical studies on the efficacy of taurine for the treatment of rheumatoid arthritis. Amino Acids 53(6):783\u2013800","journal-title":"Amino Acids"},{"issue":"1","key":"2073_CR103","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1146\/annurev-animal-020420-033029","volume":"10","author":"W Ye","year":"2022","unstructured":"Ye W, Chen Q (2022) Potential applications and perspectives of humanized mouse models. Annu Rev Anim Biosci 10(1):395\u2013417","journal-title":"Annu Rev Anim Biosci"},{"key":"2073_CR104","unstructured":"Carlos J (2021) Immunopathogenesis and preclinical testing of Cell-Based Therapies. Tolerogenic dendritic cells and regulatory T cells as therapeutics for Immune-Mediated disorders. Nov 16"},{"key":"2073_CR105","doi-asserted-by":"crossref","unstructured":"Sorosina M et al (2023) Risk HLA variants affect the T-cell repertoire in multiple sclerosis. Neurol Neuroimmunol Neuroinflammation 10(3):e200093","DOI":"10.1212\/NXI.0000000000200093"},{"key":"2073_CR106","doi-asserted-by":"publisher","first-page":"689711","DOI":"10.3389\/fmed.2022.689711","volume":"9","author":"VC Rom\u00e3o","year":"2022","unstructured":"Rom\u00e3o VC, Fonseca JE (2022) Disease mechanisms in preclinical rheumatoid arthritis: a narrative review. Front Med 9:689711","journal-title":"Front Med"},{"key":"2073_CR107","doi-asserted-by":"publisher","first-page":"680043","DOI":"10.3389\/fphar.2021.680043","volume":"12","author":"S Shams","year":"2021","unstructured":"Shams S et al (2021) The therapeutic landscape of rheumatoid arthritis: current state and future directions. Front Pharmacol 12:680043","journal-title":"Front Pharmacol"},{"issue":"19","key":"2073_CR108","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1016\/S0024-3205(97)00480-3","volume":"61","author":"LK Myers","year":"1997","unstructured":"Myers LK et al (1997) Collagen-induced arthritis, an animal model of autoimmunity. Life Sci 61(19):1861\u20131878","journal-title":"Life Sci"},{"key":"2073_CR109","unstructured":"Weber L (2018) Development of macromolecular prodrugs for the treatment of chronic inflammatory pain. Theses Diss 323. https:\/\/digitalcommons.unmc.edu\/etd\/323"},{"issue":"5","key":"2073_CR110","doi-asserted-by":"publisher","first-page":"e20191421","DOI":"10.1084\/jem.20191421","volume":"217","author":"C Louis","year":"2020","unstructured":"Louis C et al (2020) NK cell\u2013derived GM-CSF potentiates inflammatory arthritis and is negatively regulated by CIS. J Exp Med 217(5):e20191421","journal-title":"J Exp Med"},{"key":"2073_CR111","unstructured":"Guerard S (2016) Investigation of T cell driven arthritis induced by mannan in ZAP70 mutated SKG mice. Karolinska Institutet. Thesis. https:\/\/hdl.handle.net\/10616\/45216"},{"issue":"2","key":"2073_CR112","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.rdc.2010.02.006","volume":"36","author":"S Sarkar","year":"2010","unstructured":"Sarkar S, Fox DA (2010) Targeting IL-17 and Th17 cells in rheumatoid arthritis. Rheumatic Disease Clin 36(2):345\u2013366","journal-title":"Rheumatic Disease Clin"},{"issue":"3","key":"2073_CR113","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41571-022-00721-2","volume":"20","author":"J Chuprin","year":"2023","unstructured":"Chuprin J et al (2023) Humanized mouse models for immuno-oncology research. Nat Rev Clin Oncol 20(3):192\u2013206","journal-title":"Nat Reviews Clin Oncol"},{"issue":"12","key":"2073_CR114","doi-asserted-by":"publisher","first-page":"20206","DOI":"10.1021\/acsnano.2c05643","volume":"16","author":"KA Brzezicka","year":"2022","unstructured":"Brzezicka KA et al (2022) Suppression of autoimmune rheumatoid arthritis with hybrid nanoparticles that induce B and T cell tolerance to self-antigen. ACS Nano 16(12):20206\u201320221","journal-title":"ACS Nano"},{"issue":"6","key":"2073_CR115","doi-asserted-by":"publisher","first-page":"e16673","DOI":"10.1016\/j.heliyon.2023.e16673","volume":"9","author":"MA Ansari","year":"2023","unstructured":"Ansari MA et al (2023) Rituximab exerts its anti-arthritic effects via inhibiting NF-\u03baB\/GM-CSF\/iNOS signaling in B cells in a mouse model of collagen-induced arthritis. Heliyon 9(6):e16673. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e16673","journal-title":"Heliyon"},{"key":"2073_CR116","doi-asserted-by":"publisher","first-page":"174480692210977","DOI":"10.1177\/17448069221097760","volume":"18","author":"Y Fan","year":"2022","unstructured":"Fan Y et al (2022) Systematic analysis of inflammation and pain pathways in a mouse model of gout. Mol Pain 18:17448069221097760. https:\/\/doi.org\/10.1177\/17448069221097760","journal-title":"Mol Pain"},{"issue":"3","key":"2073_CR117","doi-asserted-by":"publisher","first-page":"263","DOI":"10.34172\/PS.2023.7","volume":"29","author":"LR Singha","year":"2023","unstructured":"Singha LR, Das MK (2023) Role of preclinical arthritis models for the clinical translation of anti-arthritic therapeutics. Pharm Sci 29(3):263\u2013282","journal-title":"Pharm Sci"},{"issue":"1","key":"2073_CR118","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3390\/ijms24010353","volume":"24","author":"MW Wargocka","year":"2022","unstructured":"Wargocka MW et al (2022) Recent advances in cardiovascular diseases research using animal models and PET radioisotope tracers. Int J Mol Sci 24(1):353","journal-title":"Int J Mol Sci"},{"key":"2073_CR119","doi-asserted-by":"publisher","first-page":"108793","DOI":"10.1016\/j.clim.2021.108793","volume":"230","author":"S Liu","year":"2021","unstructured":"Liu S et al (2021) Recent advances on signaling pathways and their inhibitors in rheumatoid arthritis. Clin Immunol 230:108793","journal-title":"Clin Immunol"},{"issue":"12","key":"2073_CR120","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/nrrheum.2017.187","volume":"13","author":"JR Kalden","year":"2017","unstructured":"Kalden JR, Schulze KH (2017) Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment. Nat Rev Rheumatol 13(12):707\u2013718","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"2073_CR121","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s40259-023-00634-1","volume":"38","author":"AB Avci","year":"2024","unstructured":"Avci AB, Feist E, Burmester GR (2024) Targeting IL-6 or IL-6 receptor in rheumatoid arthritis: what have we learned? BioDrugs 38(1):61\u201371","journal-title":"BioDrugs"},{"issue":"4","key":"2073_CR122","doi-asserted-by":"publisher","first-page":"103276","DOI":"10.1016\/j.autrev.2023.103276","volume":"22","author":"M Benucci","year":"2023","unstructured":"Benucci M et al (2023) JAK inhibitors and autoimmune rheumatic diseases. Autoimmun Rev 22(4):103276","journal-title":"Autoimmun Rev"},{"issue":"2","key":"2073_CR123","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41584-023-01062-9","volume":"20","author":"Z Szekanecz","year":"2024","unstructured":"Szekanecz Z et al (2024) Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician. Nat Rev Rheumatol 20(2):101\u2013115","journal-title":"Nat Rev Rheumatol"},{"key":"2073_CR124","doi-asserted-by":"publisher","first-page":"107392","DOI":"10.1016\/j.intimp.2021.107392","volume":"93","author":"Z Wu","year":"2021","unstructured":"Wu Z et al (2021) Fibroblast-like synoviocytes in rheumatoid arthritis: surface markers and phenotypes. Int Immunopharmacol 93:107392","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"2073_CR125","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41573-020-0082-8","volume":"20","author":"AA Zarrin","year":"2021","unstructured":"Zarrin AA et al (2021) Kinase Inhibition in autoimmunity and inflammation. Nat Rev Drug Discovery 20(1):39\u201363","journal-title":"Nat Rev Drug Discovery"},{"issue":"3","key":"2073_CR126","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","volume":"20","author":"DS Lee","year":"2021","unstructured":"Lee DS, Rojas OL, Gommerman JL (2021) B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nat Rev Drug Discovery 20(3):179\u2013199","journal-title":"Nat Rev Drug Discovery"},{"issue":"2","key":"2073_CR127","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/art.41417","volume":"73","author":"KD Deane","year":"2021","unstructured":"Deane KD, Holers VM (2021) Rheumatoid arthritis pathogenesis, prediction, and prevention: an emerging paradigm shift. Arthritis Rheumatol 73(2):181\u2013193","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"2073_CR128","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","volume":"117","author":"D Tracey","year":"2008","unstructured":"Tracey D et al (2008) Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 117(2):244\u2013279","journal-title":"Pharmacol Ther"},{"issue":"6","key":"2073_CR129","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS et al (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological DMARDs. Ann Rheum Dis 79(6):685\u2013699","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2073_CR130","first-page":"971","volume":"43","author":"T Tanaka","year":"2016","unstructured":"Tanaka T, Narazaki M, Kishimoto T (2016) IL-6 in inflammation, immunity, and disease. Immunity 43(6):971\u2013982","journal-title":"Immunity"},{"issue":"17","key":"2073_CR131","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1007\/s40265-017-0829-7","volume":"77","author":"LJ Scott","year":"2017","unstructured":"Scott LJ, Tocilizumab (2017) A review in rheumatoid arthritis. Drugs 77(17):1865\u20131879","journal-title":"Drugs"},{"issue":"7","key":"2073_CR132","first-page":"102493","volume":"19","author":"M Cutolo","year":"2020","unstructured":"Cutolo M et al (2020) Abatacept: mechanistic insights and clinical applications. Autoimmun Rev 19(7):102493","journal-title":"Autoimmun Rev"},{"issue":"8","key":"2073_CR133","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1002\/art.21201","volume":"52","author":"MC Genovese","year":"2005","unstructured":"Genovese MC et al (2005) Abatacept for rheumatoid arthritis refractory to TNF antagonists. Arthr Rhuem 52(8):2263\u20132271","journal-title":"Arthr Rhuem"},{"issue":"25","key":"2073_CR134","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1056\/NEJMoa032534","volume":"350","author":"JCW Edwards","year":"2004","unstructured":"Edwards JCW et al (2004) Efficacy of B-cell\u2013targeted therapy with rituximab in rheumatoid arthritis. N Engl J Med 350(25):2572\u20132581","journal-title":"N Engl J Med"},{"issue":"suppl2","key":"2073_CR135","first-page":"ii3","volume":"55","author":"EM Vital","year":"2016","unstructured":"Vital EM, Emery P (2016) The development of rituximab for the treatment of rheumatoid arthritis. Rheumatology 55(suppl2):ii3\u2013ii7","journal-title":"Rheumatology"},{"issue":"12","key":"2073_CR136","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1002\/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2","volume":"41","author":"B Bresnihan","year":"1998","unstructured":"Bresnihan B et al (1998) Treatment of rheumatoid arthritis with Recombinant human interleukin-1 receptor antagonist. Arthr Rhuem 41(12):2196\u20132204","journal-title":"Arthr Rhuem"},{"issue":"26","key":"2073_CR137","first-page":"2467","volume":"372","author":"G Cavalli","year":"2015","unstructured":"Cavalli G, Dinarello CA (2015) Anakinra therapy in autoinflammatory diseases. N Engl J Med 372(26):2467\u20132470","journal-title":"N Engl J Med"},{"issue":"4","key":"2073_CR138","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.immuni.2012.03.014","volume":"36","author":"JJ O\u2019Shea","year":"2012","unstructured":"O\u2019Shea JJ, Plenge R (2012) JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 36(4):542\u2013550","journal-title":"Immunity"},{"key":"2073_CR139","unstructured":"FDA (2021) FDA Drug safety communication: risk of serious heart-related events, cancer, blood clots, and death with JAK inhibitors"},{"issue":"10","key":"2073_CR140","doi-asserted-by":"crossref","first-page":"13396","DOI":"10.1096\/fj.202000966RR","volume":"34","author":"BN Cronstein","year":"2020","unstructured":"Cronstein BN, Aune TM (2020) Methotrexate and its mechanisms of action in inflammation. FASEB J 34(10):13396\u201313412","journal-title":"FASEB J"},{"issue":"16","key":"2073_CR141","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMra050541","volume":"353","author":"T Rhen","year":"2005","unstructured":"Rhen T, Cidlowski JA (2005) Antiinflammatory action of glucocorticoids\u2014new mechanisms for old drugs. N Engl J Med 353(16):1711\u20131723","journal-title":"N Engl J Med"},{"key":"2073_CR142","unstructured":"Grosser T, Smyth EM, FitzGerald GA (2018) Anti-inflammatory, antipyretic, and analgesic agents; pharmacotherapy of gout. Goodman & Gilman\u2019s the pharmacological basis of therapeutics, 13th edn. McGraw-Hill"},{"issue":"12","key":"2073_CR143","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1161\/CIRCULATIONAHA.106.181424","volume":"115","author":"EM Antman","year":"2007","unstructured":"Antman EM et al (2007) Use of nonsteroidal antiinflammatory drugs: an update from the American heart association. Circulation 115(12):1634\u20131642","journal-title":"Circulation"},{"issue":"1","key":"2073_CR144","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS (2023) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 82(1):3\u201318. https:\/\/doi.org\/10.1136\/ard-2022-223356Epub 2022 Nov 10","journal-title":"Ann Rheum Dis"},{"key":"2073_CR145","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3899\/jrheum.090131","volume":"82","author":"V Bykerk","year":"2009","unstructured":"Bykerk V (2009) Unmet needs in rheumatoid arthritis. J Rheumatol Supplement 82:42\u201346. https:\/\/doi.org\/10.3899\/jrheum.090131","journal-title":"J Rheumatol Supplement"},{"key":"2073_CR146","doi-asserted-by":"publisher","unstructured":"Moreland L (2005) Unmet needs in rheumatoid arthritis. Arthritis Res Ther Suppl 37. https:\/\/doi.org\/10.1186\/ar1736","DOI":"10.1186\/ar1736"},{"issue":"3","key":"2073_CR147","doi-asserted-by":"publisher","first-page":"21","DOI":"10.55248\/gengpi.5.0224.0421","volume":"1","author":"A Kumar","year":"2024","unstructured":"Kumar A, Metta D (2024) AI-driven precision oncology: predictive biomarker discovery and personalized treatment optimization using genomic data. Int J Adv Res Publ Rev 1(3):21\u201338","journal-title":"Int J Adv Res Publ Rev"},{"issue":"12","key":"2073_CR148","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41584-022-00845-w","volume":"18","author":"CM Lin","year":"2022","unstructured":"Lin CM, Cooles FA, Isaacs JD (2022) Precision medicine: the precision gap in rheumatic disease. Nat Rev Rheumatol 18(12):725\u2013733","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"2073_CR149","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41581-023-00720-1","volume":"19","author":"DS Pisetsky","year":"2023","unstructured":"Pisetsky DS (2023) Pathogenesis of autoimmune disease. Nat Rev Nephrol 19(8):509\u2013524","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"2073_CR150","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3322\/caac.21652","volume":"71","author":"LW Elmore","year":"2021","unstructured":"Elmore LW et al (2021) Blueprint for cancer research: critical gaps and opportunities. Cancer J Clin 71(2):107\u2013139","journal-title":"Cancer J Clin"},{"key":"2073_CR151","doi-asserted-by":"publisher","first-page":"1409555","DOI":"10.3389\/fimmu.2024.1409555","volume":"15","author":"Y Shi","year":"2024","unstructured":"Shi Y et al (2024) Advancing precision rheumatology: applications of machine learning for rheumatoid arthritis management. Front Immunol 15:1409555","journal-title":"Front Immunol"},{"issue":"10302","key":"2073_CR152","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S0140-6736(21)00438-4","volume":"398","author":"DP McLornan","year":"2021","unstructured":"McLornan DP et al (2021) Current and future status of JAK inhibitors. Lancet 398(10302):803\u2013816","journal-title":"Lancet"},{"key":"2073_CR153","doi-asserted-by":"publisher","first-page":"720694","DOI":"10.3389\/fphar.2021.720694","volume":"12","author":"J Peng","year":"2021","unstructured":"Peng J et al (2021) Machine learning techniques for personalised medicine approaches in immune-mediated chronic inflammatory diseases: applications and challenges. Front Pharmacol 12:720694","journal-title":"Front Pharmacol"},{"issue":"4","key":"2073_CR154","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3899\/jrheum.2023-0334","volume":"51","author":"LJ O\u2019Neil","year":"2024","unstructured":"O\u2019Neil LJ, Alp\u00edzar RD, Deane KD (2024) Rheumatoid arthritis: the continuum of disease and strategies for prediction, early intervention, and prevention. J Rhuematol 51(4):337\u2013349","journal-title":"J Rhuematol"},{"issue":"4","key":"2073_CR155","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1037\/pspp0000358","volume":"120","author":"U Orth","year":"2021","unstructured":"Orth U et al (2021) Testing prospective effects in longitudinal research: comparing seven competing cross-lagged models. J Personal Soc Psychol 120(4):1013","journal-title":"J Personal Soc Psychol"},{"issue":"3\u20134","key":"2073_CR156","doi-asserted-by":"publisher","first-page":"2000235","DOI":"10.1002\/pmic.202000235","volume":"21","author":"TD Veenstra","year":"2021","unstructured":"Veenstra TD (2021) Omics in systems biology: current progress and future outlook. Proteomics 21(3\u20134):2000235","journal-title":"Proteomics"},{"key":"2073_CR157","doi-asserted-by":"publisher","first-page":"1381272","DOI":"10.3389\/fimmu.2024.1381272","volume":"15","author":"X Gong","year":"2024","unstructured":"Gong X et al (2024) An overview of multi-omics technologies in rheumatoid arthritis: applications in biomarker and pathway discovery. Front Immunol 15:1381272","journal-title":"Front Immunol"},{"issue":"1","key":"2073_CR158","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41540-022-00247-4","volume":"8","author":"R Yue","year":"2022","unstructured":"Yue R, Dutta A (2022) Computational systems biology in disease modeling and control, review and perspectives. Npj Syst Biol Appl 8(1):37","journal-title":"Npj Syst Biology Appl"},{"key":"2073_CR159","doi-asserted-by":"publisher","first-page":"715894","DOI":"10.3389\/fimmu.2021.715894","volume":"12","author":"S Kemble","year":"2021","unstructured":"Kemble S, Croft AP (2021) Critical role of synovial tissue\u2013resident macrophage and fibroblast subsets in the persistence of joint inflammation. Front Immunol 12:715894","journal-title":"Front Immunol"},{"key":"2073_CR160","doi-asserted-by":"publisher","first-page":"1759720X2311771","DOI":"10.1177\/1759720X231177116","volume":"15","author":"A Sandhu","year":"2023","unstructured":"Sandhu A et al (2023) Emerging molecular biomarkers in osteoarthritis pathology. Therapeutic Adv Musculoskelet Disease 15:1759720X231177116","journal-title":"Therapeutic Adv Musculoskelet Disease"},{"issue":"1","key":"2073_CR161","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/rai2.12010","volume":"1","author":"P Puri","year":"2021","unstructured":"Puri P et al (2021) Understand SLE heterogeneity in the era of omics, big data, and artificial intelligence. Rheumatol Autoimmun 1(1):40\u201351","journal-title":"Rheumatol Autoimmun"},{"issue":"4","key":"2073_CR162","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1002\/cpt.3153","volume":"115","author":"N Terranova","year":"2024","unstructured":"Terranova N, Venkatakrishnan K (2024) Machine learning in modeling disease trajectory and treatment outcomes: an emerging enabler for model-informed precision medicine. Clin Pharmacol Ther 115(4):720\u2013726","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"2073_CR163","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1038\/s41591-022-01880-6","volume":"28","author":"JM Guthridge","year":"2022","unstructured":"Guthridge JM, Wagner CA, James JA (2022) The promise of precision medicine in rheumatology. Nat Med 28(7):1363\u20131371","journal-title":"Nat Med"},{"key":"2073_CR164","doi-asserted-by":"publisher","unstructured":"Chen C et al (2020) Applications of multi-omics analysis in human diseases. Med. Comm. 2023;4(4):e315. https:\/\/doi.org\/10.1002\/mco2.315","DOI":"10.1002\/mco2.315"},{"issue":"7","key":"2073_CR165","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.3390\/biomedicines12071496","volume":"12","author":"AE Mohr","year":"2024","unstructured":"Mohr AE et al (2024) Navigating challenges and opportunities in multi-omics integration for personalized healthcare. Biomedicines 12(7):1496. https:\/\/doi.org\/10.3390\/biomedicines12071496","journal-title":"Biomedicines"},{"issue":"1","key":"2073_CR166","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3390\/biomedicines13010167","volume":"13","author":"M Tanaka","year":"2025","unstructured":"Tanaka M (2025) From serendipity to precision: integrating AI, multi-omics, and human-specific models for personalized neuropsychiatric care. Biomedicines 13(1):167","journal-title":"Biomedicines"},{"issue":"1","key":"2073_CR167","doi-asserted-by":"publisher","first-page":"335","DOI":"10.30574\/wjarr.2024.21.1.0016","volume":"21","author":"TO Olorunsogo","year":"2024","unstructured":"Olorunsogo TO et al (2024) Bioinformatics and personalized medicine in the US: a comprehensive review: scrutinizing the advancements in genomics and their potential to revolutionize healthcare delivery. World J Adv Res Rev 21(1):335\u2013351","journal-title":"World J Adv Res Reviews"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-02073-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-025-02073-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-02073-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T17:02:42Z","timestamp":1769706162000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-025-02073-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":167,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["2073"],"URL":"https:\/\/doi.org\/10.1007\/s10787-025-02073-6","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]},"assertion":[{"value":"15 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors declare that there is no conflict of interest regarding the publication of this review article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable, as this article does not contain any studies involving human or animal subjects performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}